November 13th, 2011
Epcot for Foodie Cardiologists
Reva Balakrishnan, MD, MPH
Epcot’s survey of food from around the world sure beats this fellow’s memories of astronaut ice cream at Disney theme parks
November 13th, 2011
ISAR-REACT 4: Bivalirudin Works Great, Less Bleeding
Richard A. Lange, MD, MBA
In the previously published REPLACE-2 and ACUITY trials, a trend was noted towards an increased incidence of ischemic complications with bivalirudin compared with glycoprotein IIb/IIIa treatment in high-risk patients undergoing PCI. The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 (ISAR-REACT 4) trial was designed to show whether abciximab plus unfractionated […]
November 13th, 2011
An Unexpected Preconference Overload
Eiman Jahangir, MD
Anyone else surprised by the volume of ad-driven snail mail and email–most of it junk–we all got in the run up to the conference?
November 13th, 2011
Part of the System
John Ryan, MD
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. The first AHA meeting that I went to was three years ago. It […]
November 13th, 2011
ADOPT Fails to Support Extended Oral Apixaban in High-Risk Post-Discharge Patients
Larry Husten, PHD
Although medically ill patients remain at risk for VTE after hospital discharge, a strategy of extended oral anticoagulation with apixaban did not prove to be successful in the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which was presented by Samuel Z. Goldhaber at the American Heart Association and published simultaneously in the New England […]
November 13th, 2011
ATLAS ACS 2-TIMI 51: Rivaroxaban Benefits Low-Risk ACS Patients
Larry Husten, PHD
Results of the highly anticipated ATLAS-ACS 2–TIMI 51 trial demonstrate that ACS patients receiving standard therapy, including dual antiplatelet therapy, may benefit from the addition of the factor Xa inhibitor rivaroxaban, although at the cost of some additional bleeding complications. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome trial was […]
November 13th, 2011
TRACER: Novel Antiplatelet Vorapaxar Runs Into Trouble in ACS
Larry Husten, PHD
The novel antiplatelet vorapaxar, which blocks the thrombin receptor to inhibit platelet activation, ran into trouble in the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, which was stopped prematurely earlier this year due to safety concerns. TRACER was presented at the AHA by Ken Mahaffey and published simultaneously in the New England Journal […]
November 12th, 2011
Controversy Over Cholesterol Testing for Children
Larry Husten, PHD
New guidelines from the NHLBI and the American Academy of Pediatrics recommend that all children age 9 to 11 should undergo cholesterol screening. Screening should then be repeated at 17 and 21 years of age. The new guidelines are scheduled to be officially introduced by panel member Patrick McBride at the AHA in Orlando on Sunday. […]
November 12th, 2011
AHA.11: How Does One Choose What to Do?
Eiman Jahangir, MD
Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange. The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the first post here. Check back often to learn about the biggest buzz in Orlando. Sitting in the plane, waiting for it to take off, I think of […]
November 12th, 2011
AHA.11: An Orlando Eating Tour
John Ryan, MD
As at previous major cardiology meetings, CardioExchange has fellows from around the country blogging about their experiences at the Scientific Sessions at the AHA. Revathi Balakrishnan, first-year fellow at NYU; Eiman Jahangir, third-year fellow from Vanderbilt; Amit Shah, second-year fellow at Emory; and John Ryan, third-year fellow at University of Chicago will be sharing us with […]